ImmunGene raises $9m in Series A

ImmunGene has secured $9 million in a Series A financing from Ally Bridge Group. ImmunGene is a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer.

North AmericaUSBriefs